ESH Video


April 13, 2023


2nd How I Manage



Save the date: September 29 - October 1, 2023

Berlin, Germany



Chairs: Ulrich Jäger (Vienna),
Marie José Kersten (Amsterdam), Loretta Nastoupil (Houston)



Have you submitted your abstract yet?
Proceed now!



Deadline for abstracts and clinical cases for oral or poster presentation: July 2nd, 2023 (23:59 CEST)



About the Conference:

CAR-T cells and bispecific antibodies

CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies. The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies will also be discussed.

The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, ensuring a maximum level of interaction between faculty and registered participants. In addition to the scientific and medical issues addressed during the conference, the questions of affordability of and access to these novel expensive treatments will be tackled by medical experts, representatives of patient organisations, economists, regulatory authorities and industry.




Main scientific topics:

- Non-hodgkin lymphoma (NHL)
- Multiple myeloma
- Novel indications CAR T-cell therapy
- Managing toxicity of CAR-T and bispecific antibody treatment
- Real world data CAR-T
- Life after CAR T-cell therapy


Learning objectives

- Understanding of the current landscape of bispecific antibodies in NHL, MM and ALL.
- Understanding of the current landscape of CAR-T cell therapy in NHL, MM and ALL
- Novel approaches and technologies in the field
- Integration of novel therapies into current clinical practice
- Understanding the management of side effects of CAR T-cell therapy and bispecific antibodies
- Understand potential indications and sequencing of CAR-T cells and bispecifics



The programme will include:

Keynote Lecture - Plenary Sessions
Meet the Expert Sessions - Roundtables
Debates - Mentored Poster Walks
Brief Oral Communications

For more information, click here!




With the support of*:


Major Conference Partner


Supporting Conference Partner


*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.